Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase II study of CDX-110 with radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme

		Keywords:		CDX-110, temozolomide

		Phase:		Phase 2

		Treatment ID#s:		VT1899 2007-0263

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Newly Diagnosed: Y Recurrent: N Prior Surgery is Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Sometimes Allowed newly diagnosed glioblastoma multiforme

		Last Updated:		04/03/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:		CDX-110 is a vaccine based on a peptide from a variant of the epidermal growth factor (EGFRvIII), which is present in multiple cancer types but rare in normal tissue. Eligible patients need documented EGFRvIII expression in tumor tissue.

		Treatment Type:		Chemotherapy Immunological, Biological or Targeted Therapy.

		Contact:		MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By